Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387932 · ClinicalTrials.gov registry record · Phase 3
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
A Phase 3 study, sponsored by Merit Medical Systems.
- Terminated
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
NCT01387932 is a Phase 3 study that was terminated before completion, run by Merit Medical Systems. The registered enrollment target is 235 participants.
The verdict
NCT01387932, a Phase 3 study, was terminated before completion, sponsored by Merit Medical Systems.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to conventional transarterial chemoembolization with particle PVA, lipiodol, and doxorubicin.
Interventions
- DEVICE HepaSphere/QuadraSphere Microspheres
- PROCEDURE PVA, lipiodol, doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2011-06 |
| Est. Completion | 2021-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387932
The ClinicalTrials.gov registry entry for NCT01387932 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HepaSphere/QuadraSphere Microspheres is the first listed.
NCT01387932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387932 about?
NCT01387932 is a clinical study titled "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer". The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to conventional transarterial chemoembolization with particle PVA, lipiodol, and ...
What is the current status of trial NCT01387932?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2011-06. Estimated completion is 2021-02.
What interventions are being tested in trial NCT01387932?
The interventions under investigation include: HepaSphere/QuadraSphere Microspheres (DEVICE), PVA, lipiodol, doxorubicin (PROCEDURE).
Who is sponsoring clinical trial NCT01387932?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.